Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

50

Revenue 2017

Levemir

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Levemir was produced by Novo Nordisk.

Novo says real-world data backs its insulin switching

Novo says real-world data backs its insulin switching

It showed that switching to Tresiba (insulin from another basal insulin - mainly Sanofi's Lantus (insulin glargine U100) or Novo's own Levemir (insulin detemir) brand - improved blood glucose control and

Lilly and Boehringer launch first Lantus clone Basaglar in US

Lilly and Boehringer launch first Lantus clone Basaglar in US Nordisk's Levemir (insulin detemir) and Tresiba (insulin degludec). ... The list price of Basaglar in the US is $316.85 for a pack of five autoinjector pens, which also undercuts Sanofi's Lantus follow-up Toujeo, as well as Levemir

Sanofi fires off another lawsuit against a Lantus biosimilar

Sanofi fires off another lawsuit against a Lantus biosimilar Lantus made more than $7bn in sales last year but is already showing the effects of competition from biosimilars and other branded basal insulin rivals such as Novo Nordisk's Levemir

Lilly and Boehringer launch Lantus biosimilar in UK

Lilly and Boehringer launch Lantus biosimilar in UK Lantus is also being squeezed by Novo Nordisk's rival basal insulin Levemir (insulin detemir) which has been growing strongly with sales approaching $2.5bn last year, while Merck &Co and

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics